Company history

Inabata begins in October 1890, when Inabata Katsutaro opened a dyestuff shop just east of Kyoto’s Sanjo Ohashi bridge. Born in 1862 as the eldest son of a Kyoto confectioner that supplied the imperial court, he had been picked at fifteen as one of eight students Kyoto Prefecture sent to France in 1877. He studied dyeing at the La Martinière technical school in Lyon and then spent three years as an apprentice on the floor of the Marnas dye works outside the city, returning to Japan in 1885 by way of the prefectural government and a post as chief engineer at a Kyoto textile mill.

The business he built on that training inverted the normal arrangement. Japanese dyers of the day bought European chemicals through trading houses and took the seller’s word for what the drums contained and how to use them; Inabata, agent for the French maker Saint-Denis, imported directly and taught the dyeing method as he sold. Knowing the process was the moat a middleman could not cross — and the direct line to European manufacturers, rather than any plant of his own, was the asset the company would keep compounding.

The founder’s reach ran well past dyes. He registered the “IK” mark in 1891, renamed the firm Inabata Shoten in 1893, opened a Tokyo office in 1894, and in 1897 obtained a Cinématographe and its exhibition rights from the Lumière brothers, his Lyon contemporaries — staging Japan’s first film screening and then its first paid public showing in Osaka. He quit the film business within a few years to concentrate on dyes, but the pattern was set: move the base to Osaka, widen the import list to industrial chemicals, spinning and dyeing machinery, sundries and wine; found the maker Nippon Senryo Seizo in 1916 and take its presidency in 1926; incorporate in 1918 with ¥1 million of capital; add pharmaceuticals in the 1930s; and in April 1943 drop “shop” from the name altogether to become Inabata Sangyo.

Wartime materials control cut the direct import line, and with it the whole basis of an independent importer. In 1944 the maker the founder had built, Nippon Senryo Seizo, was absorbed into Sumitomo Chemical; in July of the same year Inabata was named sole distributor for Sumitomo Chemical’s dyes, chemicals and pharmaceuticals. What the family kept through the war was not a factory or a technology but the channel — the right to decide whose goods went where. That trade, made under duress, defined the company for the next half-century: no raw materials of its own, and a supplier so central that by the early 1980s Sumitomo-related purchases were still more than 30% of everything Inabata bought.

The founder died in February 1949 at eighty-seven, and in the same year the company began handling Monsanto’s PVC resin — the first step off the single dye leg. In 1957 the second president, Inabata Taro, travelled to the Italian chemical group Montecatini and signed a provisional import contract; in 1959 Inabata held the rights to the first polypropylene ever imported into Japan. Few trading houses could reach a European patent holder directly, and that old habit paid off exactly as it had in dyes.

Polypropylene then went where the economy went — car parts, appliance housings, packaging — and by the 1960s the resin desk was earning more than the dye desk that had founded the firm. Listings followed on the Osaka second section (1961), Tokyo second section (1962) and both first sections (1973). In March 1970 the company adopted a divisional headquarters structure — dyes, chemicals, synthetic resins, machinery — the moment a dye importer formally reorganised itself as a general trading house.

In November 1976 Inabata opened its first postwar overseas office, in Singapore. Less than two years later it put a resin-compounding plant in the same city through a joint venture with Sanyo Kako — a decision that made a trading house, for the first time, a manufacturer. New York followed in 1978, then Thailand (1987), Hong Kong (1988), Taiwan (1989), France (1990), Indonesia (1991), Dongguan (1995), Shanghai (1996) and the Philippines (1998). The template never varied: a sales office and a compounding plant in the same place, so that the selling function and the processing function ran as one business rather than two.

The other half of the period was subtraction. In October 1984 Inabata transferred its pharmaceuticals business to Sumitomo Pharmaceuticals, a joint venture it had set up with Sumitomo Chemical eight months earlier — ending forty-five years of direct drug distribution, and by 2005 selling down even the equity stake. Leadership stayed in the family throughout: Katsutaro, then Taro, then — after a single outside president, Ito Hideo, from 1969 to 1972 — Inabata Katsuo and, from 1998, Inabata Takeo. The centenary in 1990 was marked with a new Osaka head office, and in 1999 the business was recut into five fields: electronics, housing, chemicals, synthetic resins and foods.

Two decades of pruning narrowed the portfolio: five fields in 1999, recut in 2012, then consolidated into four in 2019 — Information & Electronics, Chemicals, Life Industry and Synthetic Resins. In the year ended March 2025 those four produced sales of ¥401.5bn, ¥264.0bn, ¥118.2bn and ¥53.7bn respectively, meaning resins and electronics alone accounted for about 79% of consolidated revenue of $5.5B (¥838bn). The polypropylene line that began with a single import right in 1959 is now roughly half the company.

Compounding grew the same way, plant by plant: Mexico in 2012 for the car makers, the Philippines in 2013, and by 2025 seven plants in seven countries with 195,000 tonnes of annual capacity — the largest such network among Japanese compounders. The dispersion turned out to be the product. When US tariffs pushed office-equipment customers to shift production out of Vietnam, Inabata could move them to its Philippine site instead of losing the work. In December 2005 the presidency passed to a sixth-generation Inabata Katsutaro, the founder’s great-grandson and namesake, who set the group’s Mission/Vision/IK Values at the 120th anniversary in 2010 and the long-range IK Vision 2030 behind it.

The most recent turn is financial rather than commercial. After three straight record years, the May 2024 medium-term plan New Challenge 2026 targets $6.3B (¥950bn) of sales and $178.2M (¥27bn) of operating profit by the year ending March 2027, and puts cost of capital at the front of the plan: sustain a price-to-book ratio above 1, hold ROE above 8%, return at least 50% of profit with a progressive dividend, and cut the cross-shareholdings accumulated through decades of distributorships by about 80% from March 2021 by March 2027. Growth is now bought as well as grown — Maruishi Chemical Products and Daigo Tsusho in 2023, Novacel in 2024 — and the year ended March 2025 set records again at $5.5B (¥838bn) of sales and $130.7M (¥20bn) of net profit, with 4,677 employees.